Myoglobin and Creatine Kinase-MB

Myoglobin and the MB isoenzyme of creatine kinase are the earlier-generation markers of myocardial necrosis. Myoglobin rises very early but is not cardiac-specific, while CK-MB is more cardiac-oriented but has been largely superseded by troponin; together they illustrate the trade-off between early release and cardiac specificity that shaped the history of cardiac biomarkers.

Definition

Myoglobin is a small oxygen-binding haem protein of cardiac and skeletal muscle that is released rapidly after muscle injury, and creatine kinase-MB is the myocardial-enriched isoenzyme of creatine kinase; both leak into the circulation following myocardial necrosis and are measured by immunoassay as markers of muscle and cardiac injury.

Scope

This topic covers the biochemistry of myoglobin and creatine kinase-MB, their release kinetics after myocardial injury, their tissue specificity, and the reasons troponin displaced them as the preferred necrosis marker. It treats both as analytes of clinical biochemistry; their relative roles are described as evidence rather than as diagnostic instructions.

Core questions

• Why does myoglobin rise earlier after injury than other cardiac markers?
• What gives CK-MB its relative cardiac orientation, and why is it not fully specific?
• How do the release kinetics of these markers compare with troponin?
• Why has troponin largely replaced CK-MB in cardiac biochemistry?
• In what residual situations might these older markers still inform measurement?

Key concepts

• Myoglobin as an early but non-specific marker
• Creatine kinase isoenzymes (CK-MM, CK-MB, CK-BB)
• CK-MB mass versus activity assays
• Release kinetics: early rise and rapid clearance
• Tissue specificity and skeletal-muscle overlap
• Relative cardiac index (CK-MB to total CK)
• Supersession by cardiac troponin

Mechanisms

Myoglobin is a low-molecular-weight cytosolic haem protein present in both cardiac and skeletal muscle; its small size lets it diffuse rapidly out of injured myocytes, so it is among the earliest markers to rise, but the same skeletal-muscle abundance makes it non-specific for the heart. Creatine kinase is a dimeric enzyme existing as MM, MB, and BB isoenzymes; the MB form is relatively enriched in myocardium, so its appearance points more toward cardiac injury, though skeletal muscle also contains some CK-MB, limiting specificity. CK-MB mass assays improved on older activity-based methods. Both markers rise and clear faster than troponin, which is why they were historically valued for early detection and for estimating reinfarction, before high-sensitivity troponin assays offered both earlier detection and far greater cardiac specificity.

Clinical relevance

Myoglobin and CK-MB are mainly of historical and educational importance now that troponin dominates, but understanding their kinetics and specificity clarifies why troponin became the reference necrosis marker. This entry describes their biochemistry as evidence; it does not provide diagnostic thresholds or treatment guidance for individual patients.

Evidence & guidelines

Reference-limit work for CK-MB mass (Apple et al., 2003) and comparative discussion of cardiac markers (Maynard et al., 2000) document the analytics of these markers, while the Fourth Universal Definition of Myocardial Infarction (Thygesen et al., 2018) positions troponin as the preferred biomarker, with CK-MB an acceptable alternative only when troponin is unavailable.

History

Creatine kinase and its MB isoenzyme were mainstays of myocardial-infarction biochemistry from the 1970s, complemented by myoglobin as an early-rising marker. The arrival of cardiac troponin assays in the 1990s, with their superior cardiac specificity, progressively displaced CK-MB and myoglobin, a transition formalised by successive Universal Definition of Myocardial Infarction documents.

Debates

Is there any remaining role for CK-MB once troponin is available?

CK-MB clears faster than troponin, which has been argued to help in estimating reinfarction timing, but troponin's greater specificity and the development of serial-troponin strategies have steadily narrowed any residual analytical advantage, and its continued use is debated.

Key figures

• Fred S. Apple
• Eugene Braunwald

Seminal works

• apple-2003
• thygesen-2019
• maynard-2000

Frequently asked questions

Why is myoglobin not specific to the heart?

Myoglobin is abundant in skeletal muscle as well as cardiac muscle, so it rises after any muscle injury; it appears very early after myocardial injury because it is a small protein that escapes damaged cells quickly, but its lack of cardiac specificity limits its usefulness on its own.

Why did troponin replace CK-MB?

Cardiac troponin is far more specific to heart muscle than CK-MB and, with sensitive assays, can be measured at much lower concentrations, so it detects smaller injuries with fewer false signals from skeletal muscle; for these reasons consensus definitions now treat troponin as the preferred necrosis marker.